10.47  0.01 (0.1%)		03-19 16:00
Open: 10.47 High: 10.47 Volume: 7,599		Pre. Close: 10.47 Low: 10.47 Market Cap: 351(M)

Short term
Mid term
Targets	6-month :	12.27	1-year :	14.33
Resists	First :	10.5	Second :	12.27
Pivot price	10.47
Supports	First :	10.43	Second :	10.39
MAs	MA(5) :	10.47	MA(20) :	10.47
	MA(100) :	10.39	MA(250) :	10.27
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	81.3	D(3) :	89
RSI	RSI(14): 53.7
52-week	High :	10.5	Low :	10.01

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ DMAA ] has closed above bottom band by 43.3%. Bollinger Bands are 11.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	10.51 - 10.57	10.57 - 10.62
Low:	10.35 - 10.4	10.4 - 10.46
Close:	10.38 - 10.47	10.47 - 10.56

Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.

Fri, 06 Mar 2026
Drugs Made In America Acquisition Corp. confirms trust account balance after affiliate irregularities - Investing.com India

Fri, 06 Mar 2026
CEO exits Drugs Made In America (NASDAQ: DMAA) after affiliate fund withdrawals - Stock Titan

Fri, 06 Mar 2026
[8-K] Drugs Made In America Acquisition Corp. Reports Material Event | DMAA SEC Filing - Form 8-K - Stock Titan

Sat, 16 Aug 2025
Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) is definitely on the radar of institutional investors who own 38% of the company - Yahoo Finance

Mon, 31 Mar 2025
Drugs Made In America Acquisition Corp. (DMAA) reports earnings - qz.com

Mon, 24 Feb 2025
Can This Power Team of Healthcare Veterans Reshape American Drug Manufacturing? - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Financial Services
Industry: Shell Companies
Shares Out	34 (M)
Shares Float	27 (M)
Held by Insiders	26.7 (%)
Held by Institutions	70.3 (%)
Shares Short	28 (K)
Shares Short P.Month	39 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.22
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-1 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	-47.6
Price to Sales	0
Price to Cash Flow	-653.36

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.